Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Giant-leaps during tumorigenesis: Dissecting saltatory evolution in cancer ‘in the making’

Descrizione del progetto

Monitorare le prime mosse del cancro

Il cancro può iniziare con notevoli modifiche improvvise del DNA, quando i cromosomi si rompono e si rimescolano in modi complessi. Questi rari salti, chiamati eventi evolutivi per salti (SEE, saltatory evolution event), possono rendere letale una cellula innocua. Ciò alimenta la crescita e la diffusione del tumore e la resistenza ai trattamenti. Ad ogni modo, le prime cellule sottoposte ai SEE rimangono nascoste, lasciando un vuoto nella comprensione di come il cancro compia il suo primo, pericoloso passo. In questo contesto, il progetto SEE-MAGIC, finanziato dal CER, intende chiarire i meccanismi alla base dei SEE. Utilizzando l’imaging guidato dall’intelligenza artificiale e la multiomica a singola cellula, i ricercatori monitoreranno le anomalie nucleari nei modelli di cancro del colon-retto. Il progetto convaliderà i risultati nei campioni di pazienti e getterà le basi per la diagnosi precoce e gli interventi di oncologia di precisione.

Obiettivo

Tumorigenesis is an evolutionary process driven by gradual mutation acquisition to confer selective advantages to somatic cells. DNA rearrangements are the most common cancer driver mutation, outnumbering base substitutions. Rearrangements amplify, disrupt and fuse genes or alter their gene regulation, ultimately driving adaptive changes to initiate cancer, metastasis and therapy resistance. Cancer genomics has revealed that most of these alterations arise as complex genomic rearrangements (CGRs), where a multitude of changes arise in a short time. While in most cases deleterious to the cell, in rare cases CGRs confer an adaptive malignant phenotype in one giant-leap through saltatory evolution events (SEEs) reminiscent of the hopeful monsters theorised by Goldschmidt. Given their potential to overcome strong selective barriers, it has been proposed that SEEs draw the line between benign lesions and lethal cancer, and understanding their mechanisms is thus fundamental to tumour biology. However, the identity of cells undergoing SEEs has remained elusive, with cancer genomics studies focusing typically on long-established cancers rather than early or even initiating cancer cells. Intriguingly, CGRs are largely explained by cascades of atypical cell nuclei (i.e. nuclear atypias) fueling rearrangement formation, providing an opportunity to study SEEs.
Building a novel automated AI-driven framework that couples imaging and single-cell multi-omics, we will leverage nuclear atypias as a phenotypic indicator to dissect principles and mechanisms of SEEs in the making, and advance fundamental cancer biology. Using highly controllable cell lines and organoid models of colorectal cancer (CrC), a tumour thought to be driven by SEEs, we will unravel pathways, genetic contexts and chromosome-level constraints determining SEEs. Finally, via validation in patient samples we will pave the way to determining SEEs in future clinical studies to advance precision oncology.

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC - HORIZON ERC Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2022-ADG

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

EUROPEAN MOLECULAR BIOLOGY LABORATORY
Contributo netto dell'UE
€ 3 428 458,00
Indirizzo
Meyerhofstrasse 1
69117 Heidelberg
Germania
Regione
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 3 428 458,00

Beneficiari (1)